{"commentary":{"count":300,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":134,"x_thread":96,"podcast":68,"x_video":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03651128\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"KarMMa-3","nct_id":"NCT03651128","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=karmma-3-nct03651128. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"KarMMa-3","arms":[{"description":"bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10\\^6 CAR+ T cells after receiving lymphodepleting chemotherapy","label":"Arm A - Administration of bb2121","type":"EXPERIMENTAL"},{"description":"The participants will receive one of following regimens dependent on the subject's most recent anti-myeloma treatment regimen:\n\n* Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose dexamethasone (dex) (DPd) OR\n* DARA in combination with bortezomib (BTZ) and low-dose dex (DVd) OR\n* Ixazomib (IXA) in combination with lenalidomide (LEN) and low-dose dex (IRd) OR\n* Carfilzomib (CFZ) in combination with low-dose dexamethasone (Kd) OR\n* Elotuzumab (ELO) in combination with POM and low-dose dexamethasone (EPd)","label":"Arm B- standard regimens as per Investigator's discretion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-04-13","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":386,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"bb2121","type":"BIOLOGICAL"},{"name":"Daratumumab","type":"DRUG"},{"name":"Pomalidomide","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"},{"name":"Bortezomib","type":"DRUG"},{"name":"Ixazomib","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Carfilzomib","type":"DRUG"},{"name":"Elotuzumab","type":"DRUG"}],"last_update":"2026-06-22","lead_sponsor":"Celgene","official_title":"A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2026-04-13","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS)","timeFrame":"Minimum of 5 years from randomization"}],"references":[{"citation":"Lopez-Munoz N, Bar N, Diels J, van Sanden S, Mendes J, Lee S, Hernando T, Lendvai N, Patel N, Ishida T, Er J, Harrison SJ. Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison. Adv Ther. 2026 Mar;43(3):1327-1340. doi: 10.1007/s12325-025-03479-y. Epub 2026 Feb 2.","pmid":"41627370","type":"DERIVED"},{"citation":"Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon S, Abrahamsen IW, Baz R, Broijl A, Chen C, Jagannath S, Raje N, Scheid C, Delforge M, Benjamin R, Pabst T, Iida S, Berdeja J, Giralt S, Truppel-Hartmann A, Chen Y, Zhong X, Wu F, Piasecki J, Eliason L, Dhanda D, Felten J, Caia A, Cook M, Popa McKiver M, Rodriguez-Otero P. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood. 2024 Dec 5;144(23):2389-2401. doi: 10.1182/blood.2024024582.","pmid":"39197072","type":"DERIVED"},{"citation":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma. Future Oncol. 2024;20(18):1221-1235. doi: 10.2217/fon-2023-0954. Epub 2024 Apr 23.","pmid":"38651976","type":"DERIVED"},{"citation":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614. Epub 2023 Feb 10.","pmid":"36762851","type":"DERIVED"}],"start_date":{"date":"2019-04-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)","url":"https://clinicaltrials.gov/study/NCT03651128"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/karmma-3-nct03651128"}